Know Cancer

or
forgot password

SCRI Tissue Testing Registry


N/A
18 Years
N/A
Open (Enrolling)
Both
Melanoma, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma

Thank you

Trial Information

SCRI Tissue Testing Registry


Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in
clinical research and correlative science. To this end, the SCRI Oncology Research
Consortium will collect written consent from patients allowing the use of their tumor tissue
sample(s) for testing/analysis at a future date. Future testing may include assays for newly
identified markers of potential prognostic and/or therapeutic value. These markers may be
specific to an individual cancer type, or they may be present more generally in cancer
and/or other conditions.

This study will consist of a registry of patients who have agreed to allow their tissue
sample(s) (even those taken prior to their participation in an SCRI-sponsored trial) to be
used by the SCRI Oncology Research Consortium at some point in the future for testing and
analysis of expression analysis and/or analysis of tumor markers. The registry will be
contained in an electronic database, and will be sorted by disease indication. (Note:
Patients will not be asked to return at a future date and have tissue samples collected;
rather, SCRI will have the authorization to obtain pre-existing samples).


Inclusion Criteria:



- Patients must be >= 18 years of age.

- Patients must be able to provide written informed consent.

Exclusion Criteria:

- Not Applicable

Type of Study:

Observational

Study Design:

Observational Model: Cohort

Outcome Measure:

To establish an electronic registry to store information from patients who have provided their consent allowing use of their tissue sample(s) for future testing.

Outcome Time Frame:

120 months

Safety Issue:

No

Principal Investigator

Howard Burris, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute

Authority:

United States: Institutional Review Board

Study ID:

SCRI MISC 39

NCT ID:

NCT00965861

Start Date:

May 2010

Completion Date:

May 2020

Related Keywords:

  • Melanoma
  • Myelodysplastic Syndrome
  • Multiple Myeloma
  • Lymphoma
  • Tissue Registry
  • Tissue Collection
  • Unknown Primary
  • Breast
  • Lung
  • Gastrointestinal
  • Bone Marrow Transplant
  • Chronic Lymphocytic Leukemia
  • Central Nervous System
  • Head and Neck
  • Melanoma
  • Myelodysplastic syndrome
  • Multiple Myeloma
  • Lymphoma
  • Gynecologic
  • Genitourinary
  • Refractory Malignancy
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Myelodysplastic Syndromes
  • Preleukemia

Name

Location

Tennessee Oncology, PLLCClarksville, Tennessee  37043